Bluebird bio Inc Total Assets
Bluebird bio Inc total assets. Based on the latest financial reports, Bluebird bio Inc (BLUE) holds total assets worth $295.96 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Bluebird bio Inc (BLUE) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Bluebird bio Inc (2011–2024)
Total assets of Bluebird bio Inc from 2011 to 2024. This chart illustrates how Bluebird bio Inc's total assets have evolved over time, based on quarterly financial data. See latest Bluebird bio Inc stock price today for real-time trading data and today's change.
Bluebird bio Inc - Asset Composition Analysis
Bluebird bio Inc Total Assets Breakdown (December 2024)
Bluebird bio Inc total assets breakdown as of December 2024. Bluebird bio Inc's total assets of $295.96 Million consist of 33.6% current assets and 66.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.5% |
| Accounts Receivable | $3.09 Million | 0.7% |
| Inventory | $65.02 Million | 14.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.55 Million | 2.1% |
| Goodwill | $5.65 Million | 1.2% |
Asset Composition Trend (2011–2024)
This chart illustrates how Bluebird bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore BLUE net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bluebird bio Inc's current assets represent 33.6% of total assets in 2024, a decrease from 97.0% in 2011.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2024, down from 82.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 14.1% of total assets.
Bluebird bio Inc Competitors by Total Assets
Key competitors of Bluebird bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Bluebird bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.55 | 0.93 | 8.18 |
| Quick Ratio | 0.29 | 0.82 | 8.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-140.55 Million | $-21.97 Million | $1.42 Billion |
Bluebird bio Inc - Advanced Valuation Insights
This section examines the relationship between Bluebird bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.73 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -25.7% |
| Total Assets | $460.23 Million |
| Market Capitalization | $48.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bluebird bio Inc's assets below their book value (0.11x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bluebird bio Inc's assets decreased by 25.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bluebird bio Inc (2011–2024)
The table below shows the annual total assets of Bluebird bio Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $460.23 Million | -25.67% |
| 2023-12-31 | $619.16 Million | +11.58% |
| 2022-12-31 | $554.90 Million | -6.55% |
| 2021-12-31 | $593.79 Million | -66.66% |
| 2020-12-31 | $1.78 Billion | +3.12% |
| 2019-12-31 | $1.73 Billion | -22.98% |
| 2018-12-31 | $2.24 Billion | +18.01% |
| 2017-12-31 | $1.90 Billion | +69.98% |
| 2016-12-31 | $1.12 Billion | +11.55% |
| 2015-12-31 | $1.00 Billion | +80.04% |
| 2014-12-31 | $556.74 Million | +148.11% |
| 2013-12-31 | $224.39 Million | +223.69% |
| 2012-12-31 | $69.32 Million | +124.21% |
| 2011-12-31 | $30.92 Million | -- |
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more